Evidence indicates that: (i) CXCR2 deletion reduces the metastatic potential of lung cancer cells [18]; (ii) in breast cancer models, CXCR2 signaling is important for attracting myeloid-derived-suppressor-cells to the TM, where they drive invasion and metastasis [19]; (iii) CXCR2 inhibition enhances T cell entry conferring sensitivity to anti-PD1 therapy in pancreatic cancer [20]; (iv) CXCR2 is a very important target for suppressing neutrophilic inflammation in breast cancer models [21]. This evidence concerns the gene CXCR2 and pancreatic neoplasm.